By Sabrina Valle NEW YORK, Jan 20 (Reuters) - Abivax Chief Executive Marc de Garidel dismissed as "noise" reports in the ...

Eli Lilly looks undervalued as earnings forecasts rise and GLP-1 catalysts near. Read the full analysis here of LLY stock.

We look at the Novo Nordisk A/S outlook for 2026: new CEO focus, oral Wegovy edge vs Eli Lilly, and double-digit growth ...

The choice isn't that hard.

Eli Lilly is getting its hands on a promising pipeline candidate thanks to an acquisition. The stock may not gain much more ...

Eli Lilly is Wednesday's IBD Stock Of The Day. Lilly shares are bounding off their 50-day line with a new buying opportunity ...

Eli Lilly and Novo Nordisk were sued by a compounding pharmacy alleging anticompetitive practices in the GLP-1 weight-loss ...

Novo Nordisk oral Wegovy records 3,071 prescriptions in four days. Shares jump 6.5% as Eli Lilly oral weight loss drug awaits ...

What happens with Eli Lilly's GLP-1 shot now that Novo Nordisk has come out with a GLP-1 pill?

Eli Lilly And Co (NYSE:LLY) and Novo Nordisk (NYSE:NVO), are reportedly being sued in Texas by compounding pharmacy Strive ...

Eli Lilly stock prepares €15B Abivax acquisition as tirzepatide revenue hits $24.8B. Orforglipron oral weight loss drug ...

Eli Lilly and Co (NYSE: LLY) has outperformed the market over the past 5 years by 25.43% on an annualized basis producing an average annual return of 37.44%. Currently, Eli Lilly and Co has a market ...